MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study
The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in subjects with metastatic pancreatic cancer.
A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma
- ClinicalTrials.gov Identifier: NCT03611556
- Protocol Number: 18-588
- Principal Investigator: Andrea Bullock
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required